+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urotensin-II and cardiovascular remodeling

Urotensin-II and cardiovascular remodeling

Peptides 29(5): 764-769

Urotensin-II (U-II), a cyclic undecapeptide, and its receptor, UT, have been linked to vascular and cardiac remodeling. In patients with coronary artery disease (CAD), it has been shown that U-II plasma levels are significantly greater than in normal patients and the severity of the disease is increased proportionally to the U-II plasma levels. We showed that U-II protein and mRNA levels were significantly elevated in the arteries of patients with coronary atherosclerosis in comparison to healthy arteries. We observed U-II expression in endothelial cells, foam cells, and myointimal and medial vSMCs of atherosclerotic human coronary arteries. Recent studies have demonstrated that U-II acts in synergy with mildly oxidized LDL inducing vascular smooth muscle cell (vSMC) proliferation. Additionally, U-II has been shown to induce cardiac fibrosis and cardiomyocyte hypertrophy leading to cardiac remodeling. When using a selective U-II antagonist, SB-611812, we demonstrated a decrease in cardiac dysfunction including a reduction in cardiomyocyte hypertrophy and cardiac fibrosis. These findings suggest that U-II is undoubtedly a potential therapeutic target in treating cardiovascular remodeling.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 034144661

Download citation: RISBibTeXText

PMID: 17988761

DOI: 10.1016/j.peptides.2007.09.012

Related references

Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1. Peptides 30(6): 1124-1129, 2009

Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction. Journal of Neurochemistry 107(2): 361-374, 2008

Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts. Peptides 27(12): 3261-3268, 2006

Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. Journal of Thrombosis and Haemostasis 6(5): 726-736, 2008

Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II. Bioorganic and Medicinal Chemistry Letters 27(15): 3412-3416, 2017

Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides (New York) 22(7): 1175-1179, 2001

The role of urotensin II in airway remodeling of asthma. Zhonghua Jie He He Hu Xi Za Zhi 29(6): 381-384, 2006

A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension. International Immunopharmacology 40: 196-202, 2016

Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27(11): 2919-2926, 2006

Urotensin II in cardiovascular regulation. Vascular Health and Risk Management 4(4): 775-785, 2008

Urotensin-II and cardiovascular diseases. Current Hypertension Reports 8(6): 479-483, 2006

Urotensin II and cardiovascular diseases. Peptides 25(10): 1789-1794, 2004

Urotensin Ii in cardiovascular regulation. Vascular Health and Risk Management Volume 4: 775-785, 2008

Urotensin II in the cardiovascular system. Peptides 25(10): 1795-1802, 2004

Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. Naunyn-Schmiedeberg's Archives of Pharmacology 376(1-2): 107-115, 2007